Our Take
Three separate cancer vaccine candidates showed measurable survival gains at ASCO 2026, but the field faces a credibility trap: mRNA skepticism from US health leadership may chill funding even as clinical data accelerates.
Why it matters
Personalized neoantigen vaccines are moving from Phase I to late-stage proof-of-concept with durable responses. Oncologists need to track which combinations work and which don't, because trial design (when to start immunotherapy relative to vaccination) directly impacts patient outcomes.
Do this week
Oncologists: audit your melanoma recurrence protocols against the KEYNOTE-942 data before Q2 2027 so you can counsel post-surgical patients on intismeran eligibility and expected timelines.
Three cancer vaccines show durable survival gains
At the American Society of Clinical Oncology meeting in 2026, three research groups presented Phase I and Phase IIb data for personalized cancer vaccines designed to prime immune response against patient-specific tumor mutations.
Moderna and Merck Sharp & Dohme's intismeran, combined with Keytruda (pembrolizumab), reduced the risk of melanoma recurrence or death by 49% in the KEYNOTE-942 trial (107 patients, five-year follow-up, per the companies). Overall survival was 92.2% in the vaccine-plus-immunotherapy arm versus 71.3% in the immunotherapy-alone arm. The vaccine also cut the risk of distant metastasis by 59% (company-reported).
Dana-Farber Cancer Institute's NeoVax, a personalized neoantigen vaccine combined with Keytruda, extended median overall survival to 36.9 months in newly diagnosed MGMT-methylated glioblastoma patients, compared to 25.3 months in propensity-matched standard-of-care controls (per Dana-Farber). This represents an 11.6-month gain. The trial enrolled patients with gross total tumor resection and used DNA, RNA sequencing, and HLA typing to identify patient-specific immunogenic mutations.
A critical finding: patients who received Keytruda after vaccine priming (cohort 1B) had inferior survival compared to those who received Keytruda before vaccination (cohorts 2 and 3). Dr. David Reardon, Clinical Director of Dana-Farber's Center for Neuro-Oncology, noted this outcome contradicted the study's prediction.
Johnson & Johnson's Rybrevant Faspro (amivantamab), a bispecific antibody given subcutaneously, achieved a 42% overall response rate in head and neck squamous cell carcinoma with more than one-third of responders reaching complete response (per the OrigAMI-4 Phase Ib/II trial). The median time to first response was 6.6 weeks, and a supplemental Biologics License Application for subcutaneous administration has been filed with the FDA following Breakthrough Therapy Designation.
Timing and political uncertainty reshape the vaccine story
The intismeran and NeoVax data confirm that mRNA-based personalized vaccines can produce durable clinical benefit in solid tumors. Melanoma survival rates above 92% at five years represent a material shift from historical baselines in high-risk populations.
However, the field faces a funding headwind. In August 2025, U.S. Health Secretary Robert F. Kennedy Jr. revoked $500 million in BARDA (Biomedical Advanced Research and Development Authority) funding earmarked for mRNA vaccine development, affecting 22 programs (per public reporting). This move introduces regulatory and political uncertainty at a moment when clinical efficacy is accelerating. Experts quoted in the source material warned that these shifts signal politicization of mRNA research despite the technology's clinical track record.
For practitioners, the intismeran melanoma data is immediately actionable. The five-year durability and specific survival rates (92.2% OS with vaccine) provide a clear benchmark for informed consent and patient counseling. The glioblastoma trial's finding that vaccine-first sequencing underperforms immunotherapy-first sequencing is a protocol-level warning that deserves close attention in any future trials or expanded access programs.
What to track and what to avoid
The KEYNOTE-942 trial enrolled only 107 patients in a Phase IIb design, meaning these results are promising but not yet standard-of-care recommendations. Regulatory approval and insurance coverage remain pending. Practitioners should monitor the intismeran regulatory pathway for decision-making timelines rather than assuming imminent availability.
The glioblastoma vaccine-sequencing finding (Keytruda before vaccination outperforms vaccination before Keytruda) is counterintuitive and should be treated as hypothesis, not law, until reproduced in larger prospective trials. If and when NeoVax enters late-stage development, enrollment strategy and sequencing protocols will be critical variables.
For melanoma and glioblastoma specialists, the takeaway is clear: personalized neoantigen vaccines are no longer speculative. They are in clinical transition. The bottleneck is now regulatory approval, manufacturing scale, and the political stability of funding, not proof of concept.